Propanc Biopharma, Inc. PPCB
We take great care to ensure that the data presented and summarized in this overview for Propanc Biopharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PPCB
Top Purchases
Top Sells
About PPCB
Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Insider Transactions at PPCB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 17
2021
|
James Andrew Nathanielsz CEO/CFO |
BUY
Grant, award, or other acquisition
|
Indirect |
8,728,000
+50.0%
|
-
|
|
Aug 17
2021
|
Julian Norman Kenyon Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,420,000
+50.0%
|
-
|